{"filing":{"accession_number":"0001493152-26-036979","cik":"0001453593","ticker":"XTNT","company_name":"Xtant Medical Holdings, Inc.","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/form8-k.htm"},"events":[{"id":26853,"run_id":24422,"accession_number":"0001493152-26-036979","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces \"financial results for the second quarter of 2026\" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 revenue of $23.0 million (down from $35.4 million in Q2 2025), a net loss of $9.4 million (versus net income of $3.6 million in Q2 2025), and revised full-year 2026 guidance to $99-103 million from $101-105 million. This is a material event affecting investor assessment of the company's financial performance and outlook.","company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28130,"accession_number":"0001493152-26-036979","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces \"financial results for the second quarter of 2026\" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 revenue of $23.0 million (down from $35.4 million in Q2 2025), a net loss of $9.4 million (versus net income of $3.6 million in Q2 2025), and revised full-year 2026 guidance to $99-103 million from $101-105 million. This is a material event affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:03.657930+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28130,"accession_number":"0001493152-26-036979","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces \"financial results for the second quarter of 2026\" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 revenue of $23.0 million (down from $35.4 million in Q2 2025), a net loss of $9.4 million (versus net income of $3.6 million in Q2 2025), and revised full-year 2026 guidance to $99-103 million from $101-105 million. This is a material event affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T11:07:03.657930+00:00","company_name":"Xtant Medical Holdings, Inc.","ticker":"XTNT","filing_date":"2026-08-11"}]}